Labcorp to acquire Toxikon, expanding nonclinical development testing capabilities for pharmaceutical, biotech and medical device clients

BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 18, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire Toxikon, a contract research organization delivering best-in-class nonclinical testing services. Once completed, the transaction will create a strategic footprint for Labcorp to partner with pharmaceutical and biotechnology clients in the Boston, Mass., area and bolster its strong nonclinical development portfolio.

Becoming a leader through the Project Management Academy

Gaining on-the-job experience to become a clinical project manager is now a lot easier with the Labcorp Project Management Academy.